Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019

Tuesday, February 19, 2019 4:30 pm EST

Dateline:

WOODCLIFF LAKE, N.J.

Public Company Information:

NASDAQ:
EGRX

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. ("Eagle" or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2018 fourth quarter and full year financial results on Thursday, February 28, 2019, before the market opens.

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date     Thursday, February 28, 2019
Time 8:30 a.m. EDT
Toll free (U.S.) 877-876-9177
International 785-424-1672
Webcast (live and replay)

www.eagleus.com, under the “Investor Relations” section

A replay of the conference call will be available for one week after the call's completion by dialing 800-283-4799 (US) or 402-220-0860 (International) and entering conference call ID EGRXQ418. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

Contact:

Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

Business Wire InvestorHQsm